In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

This bipartisan legislation prevents further cuts, provides a modest inflationary adjustment to help ease the cost of care, ...

In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.

Some regulatory changes are already set to happen this year, but reduced regulation under the new administration could have a ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

At today's confirmation hearing, Democratic senators were skeptical of the HHS Secretary nominee Robert F. Kennedy Jr.'s ...